InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2025-10-31 | Lisa McClain(R-MI09) | house | Sale | $1,001 - $15,000 |
| 2025-10-30 | Lisa McClain(R-MI09) | house | Sale | $1,001 - $15,000 |
| 2025-10-30 | Lisa McClain(R-MI09) | house | Purchase | $1,001 - $15,000 |
| 2025-06-17 | Lisa McClain(R-MI09) | house | Purchase | $1,001 - $15,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $29.1M-11.2% | $32.7M+3.8% | $31.5M | — |
| Cost of revenues | $911K-43.0% | $1.6M-47.3% | $3.0M-66.2% | $9.0M |
| Research and development (includes $39,780, $32,400 and $28,669 of share-based compensation expense for the years ended March 31, 2025, 2024 and 2023, respectively) | $550.4M+25.1% | $439.9M-3.1% | $454.1M | — |
| Acquired in-process research and development | $0-100.0% | $26.4M-72.9% | $97.7M-30.1% | $139.9M |
| General and administrative (includes $239,505, $154,873 and $175,019 of share-based compensation expense for the years ended March 31, 2025, 2024 and 2023, respectively) | $591.4M+42.1% | $416.1M+8.5% | $383.4M | — |
| Total operating expenses | $1.14B+29.3% | $884.1M-5.8% | $938.3M-33.3% | $1.41B |
| Gain on sale of Telavant net assets | $110.4M-97.9% | $5.35B | $0 | — |
| (Loss) income from operations | -$1.00B-122.3% | $4.50B+595.9% | -$906.8M | — |
| Change in fair value of investments | -$55.2M-215.0% | $48.0M+130.5% | $20.8M-76.2% | $87.3M |
| Change in fair value of liability instruments | -$15.8M-133.6% | $46.8M+154.7% | $18.4M | — |
| Gain on deconsolidation of subsidiaries | -$3.1M+90.5% | -$32.8M-11.9% | -$29.3M-480.8% | -$5.0M |
| Interest income | -$258.4M-76.5% | -$146.4M-355.0% | -$32.2M-8622.0% | -$369K |
| Other expense, net | $10.7M-20.9% | $13.6M+2690.5% | $486K | — |
| (Loss) income from continuing operations before income taxes | -$681.6M-114.9% | $4.57B+616.1% | -$885.0M | — |
| Income tax expense | $48.2M+124.0% | $21.5M+426.8% | $4.1M+1006.2% | $369K |
| (Loss) income from continuing operations, net of tax | -$545.2M-111.7% | $4.66B+694.5% | -$784.4M | — |
| Income (loss) from discontinued operations, net of tax | $373.2M+218.9% | -$313.8M-39.7% | -$224.7M | — |
| Net (loss) income | -$356.7M-108.4% | $4.23B+479.3% | -$1.12B | — |
| Net loss attributable to noncontrolling interests | -$184.8M-56.9% | -$117.7M-10.6% | -$106.4M-35.0% | -$78.9M |
| Net (loss) income attributable to Roivant Sciences Ltd. | -$172.0M-104.0% | $4.35B+531.0% | -$1.01B | — |
| (Loss) income from continuing operations, net of tax | -$545.2M-111.7% | $4.66B+694.5% | -$784.4M | — |
| Income (loss) from discontinued operations, net of tax | $373.2M+218.9% | -$313.8M-39.7% | -$224.7M | — |
| Net (loss) income attributable to Roivant Sciences Ltd. | -$172.0M-104.0% | $4.35B+531.0% | -$1.01B | — |
| (Loss) income from continuing operations, net of tax (in dollars per share) | -$750-113.4% | $6K+610.0% | -$1K | — |
| Income (loss) from discontinued operations, net of tax (in dollars per share) | $510+234.2% | -$380-18.8% | -$320 | — |
| Net (loss) income (in dollars per share) | -$240-104.6% | $5K+468.3% | -$1K | — |
| (Loss) income from continuing operations, net of tax (in dollars per share) | -$750-113.4% | $6K+610.0% | -$1K | — |
| Income (loss) from discontinued operations, net of tax (in dollars per share) | $510+234.2% | -$380-18.8% | -$320 | — |
| Net (loss) income (in dollars per share) | -$240-104.6% | $5K+468.3% | -$1K | — |
| Basic (in shares) | $725.40B-7.4% | $783.25B+9.9% | $712.79B | — |
| Diluted (in shares) | $725.40B-12.7% | $831.05B+16.6% | $712.79B | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Piper Sandler and Bernstein Bullish on Roivant Sciences (ROIV)
Roivant Sciences Ltd. (ROIV): David Einhorn Trims Stake
Roivant Sciences: Moderna Settlement And Brepocitinib Support A Long-Term Buy
Roivant Sciences Ltd. (ROIV): One of the Best Stocks to Buy According to Joe Edelman